All stock lists
Arvinas, Inc. (NASDAQ:ARVN)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
6.75-0.01 (-0.19%)
Market cap
$441M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 27, 2018
Website
Insider Score
––Not scored
ARVN Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ARVN analyst forecast
ARVN analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ARVN 12-month price target
$13.00+92.3% upsideaverage of 1 firm
$13.00High
$13.00Low
ARVN ratings mix, last 12 months
Buy Hold Sell
Best analysts covering ARVN
- Piper Sandler50%success rate · +7.0% avg return · 4 calls
- BTIG50%success rate · -6.7% avg return · 2 calls
- Stephens & Co.50%success rate · -16.1% avg return · 2 calls
- HC Wainwright & Co.44%success rate · -21.2% avg return · 16 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ARVN analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| H.C. Wainwright | — | $13.00 | +82.6% | — | 2026-11-04 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-11-03 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-08-10 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-08-10 |
| — | Wells Fargo | Equal Weight | — | — | Downgraded | 2026-08-05 |
| — | Wedbush | Neutral | — | — | Reiterated | 2026-08-05 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-04 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2026-06-03 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-13 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-05-04 |
| — | BTIG | Buy | — | — | Reiterated | 2026-03-19 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-19 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-05 |
| — | Wedbush | Neutral | — | — | Reiterated | 2026-02-25 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-02-25 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-02-25 |
| — | Citigroup | Buy | — | — | Upgraded | 2026-01-06 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-12-17 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-11-10 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-11-06 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-06 |
| — | BTIG | Buy | — | — | Reiterated | 2025-10-30 |
| — | Goldman Sachs | Sell | — | — | Downgraded | 2025-10-15 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-09-18 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-18 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-08-07 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-07 |
| — | Leerink Partners | Market Perform | — | — | Downgraded | 2025-06-02 |
| — | UBS | Buy | — | — | Reiterated | 2025-05-15 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2025-05-09 |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-05-05 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2025-05-05 |
| — | Truist Securities | Hold | — | — | Downgraded | 2025-05-05 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-05-02 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-05-02 |
| — | Jefferies | Hold | — | — | Downgraded | 2025-05-02 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-02 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-05-02 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-05-02 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-05-02 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-04-17 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-04-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-14 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-03-13 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2025-03-13 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-03-12 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2025-03-12 |
| — | Wedbush | Neutral | — | — | Downgraded | 2025-03-12 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-03-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-11 |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-03-07 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-02-12 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-02-12 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2025-02-12 |
| — | Stifel | Buy | — | — | Reiterated | 2025-02-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-02-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-02-03 |
ARVN earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-24 | -0.55 | -1.10 | $37.2M | $9.5M |
| 2026-05-12 | -0.95 | -0.90 | $16.6M | $15.6M |
| 2026-08-04 | -0.37 | 2.58 | $60.7M | $249.7M |
| 2026-11-03 | -0.92 | -0.82 | $12.4M | $500K |
| 2027-02-23Upcoming | -0.76 | — | $11.9M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.